Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022

Detalles Bibliográficos
Autores principales: O’Laughlin, Kevin, Tobolowsky, Farrell A., Elmor, Riad, Overton, Rahsaan, O’Connor, Siobhán M., Damon, Inger K., Petersen, Brett W., Rao, Agam K., Chatham-Stephens, Kevin, Yu, Patricia, Yu, Yon, Ahmadi, Sarah, Avery, Rachel, Bean, Kathryn, Beavers, Leah, Belanger Giguere, Kim, Brownlee, Joi, Campbell, Catherine, Cheng, Maggie, Clinton, Rachel, Coleman, Taylor, Davis, Monique S., Dubreus, Marie, Henry, Meryl, Lozoya, Sujeith B., Morgan, Jahnae, Muhammad, Kalimah, Parker, Corinne M., Peters, Nigel, Rybak, Ellery, Schwenk, Andrew, van Loben Sels, Jessica, Veillard,, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Full Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484807/
https://www.ncbi.nlm.nih.gov/pubmed/36107794
http://dx.doi.org/10.15585/mmwr.mm7137e1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484807/
https://www.ncbi.nlm.nih.gov/pubmed/36107794
http://dx.doi.org/10.15585/mmwr.mm7137e1

Ejemplares similares